Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,FULC,127754000,32679600,,,-16999000,,-16999000,5498000,-11545000,-17043000,-17043000,,,,,,0,4789000,21832000,16334000,44000,,-16999000,-16999000,366344000,28722000,127754000,12630000,156476000,33000,258000,-238619000,6091000,-4000,1655000,100745000,22631000,-4000,7834000,146987000,43111000,634000,4797000,12677000.0,-3338000.0,12415000.0,-13000.0,47504000.0,-638000.0,47517000.0,43693000.0,-16226000.0,603000.0,1999000.0,2147000.0,-262000.0,,,124356000,en-US,US,EQUITY,True,Nasdaq Real Time Price,26.83,1630526403,-2.8700008,29.64,29.9,26.65,956551,-10.279694,4.527,14.918056,11.911944,0.7984918,11.973116,14.856884,1.2408535,876793664,-7.9851193,5.9266624,15,America/New_York,EDT,False,False,USD,-2.61,us_market,"Fulcrum Therapeutics, Inc.",NGM,POST,2,0.63361937,1630531634,27.0,0.17000008,-9.663302,26.65 - 29.9,29.7,26.82,27.0,9,9,finmb_376267397,NasdaqGM,"Fulcrum Therapeutics, Inc.",USD,3295537,1036633,19.98,2.9167883,6.85 - 29.9,-3.0699997,-0.10267558,6.85,29.9,1620304200,1620304200,0,1620304200,-14.919,-3.36,-14400000,,,,29.9,6.85,14.92,11.97,3.3M,1.04M,32.68M,,17.56M,11.50%,80.96%,678.59k,9.65,3.82%,2.08%,743.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-543.14%,-34.74%,-69.93%,12.86M,0.47,538.50%,-46.84M,-67.42M,-69.37M,-14.92,,143.86M,4.41,4k,0.00,6.49,4.53,-54.68M,-26.04M,Value,02139,Healthcare,73,9,8,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 651 8851,MA,8,1609372800,1622505600,8,United States,http://www.fulcrumtx.com,86400,9,26 Landsdowne Street,Biotechnology
t-1,FULC,95181000,32679600,3380000.0,,-17720000,,-17720000,5867000,-8540000,-17787000,-17787000,,,,,,0,4225000,22012000,12765000,67000,,-17720000,-17720000,316775000,34396000,95181000,15423000,129577000,28000,74000,-221620000,7671000,-2000,1670000,57052000,26725000,-2000,8397000,119510000,55862000,2707000,4079000,-14126000.0,-1510000.0,-14598000.0,-13000.0,6255000.0,-1102000.0,6268000.0,-28169000.0,-19826000.0,733000.0,-1939000.0,1712000.0,-472000.0,,,92785000,en-US,US,EQUITY,True,Nasdaq Real Time Price,26.83,1630526403,-2.8700008,29.64,29.9,26.65,956551,-10.279694,4.527,14.918056,11.911944,0.7984918,11.973116,14.856884,1.2408535,876793664,-7.9851193,5.9266624,15,America/New_York,EDT,False,False,USD,-2.61,us_market,"Fulcrum Therapeutics, Inc.",NGM,POST,2,0.63361937,1630531634,27.0,0.17000008,-9.663302,26.65 - 29.9,29.7,26.82,27.0,9,9,finmb_376267397,NasdaqGM,"Fulcrum Therapeutics, Inc.",USD,3295537,1036633,19.98,2.9167883,6.85 - 29.9,-3.0699997,-0.10267558,6.85,29.9,1620304200,1620304200,0,1620304200,-14.919,-3.36,-14400000,,,,29.9,6.85,14.92,11.97,3.3M,1.04M,32.68M,,17.56M,11.50%,80.96%,678.59k,9.65,3.82%,2.08%,743.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-543.14%,-34.74%,-69.93%,12.86M,0.47,538.50%,-46.84M,-67.42M,-69.37M,-14.92,,143.86M,4.41,4k,0.00,6.49,4.53,-54.68M,-26.04M,Value,02139,Healthcare,73,9,8,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 651 8851,MA,8,1609372800,1622505600,8,United States,http://www.fulcrumtx.com,86400,9,26 Landsdowne Street,Biotechnology
t-2,FULC,104985000,32679600,3380000.0,,-18962000,,-18962000,5312000,-13792000,-19104000,-19104000,,,,,,0,1848000,20952000,15640000,142000,,-18962000,-18962000,308827000,37230000,104985000,14151000,142215000,27000,72000,-203900000,10775000,31000,1708000,85221000,26455000,31000,8395000,132112000,41804000,663000,3634000,14183000.0,11397000.0,14090000.0,-13000.0,-83000.0,585000.0,6268000.0,9503000.0,-4504000.0,554000.0,163000.0,1759000.0,-93000.0,-70000.0,,105657000,en-US,US,EQUITY,True,Nasdaq Real Time Price,26.83,1630526403,-2.8700008,29.64,29.9,26.65,956551,-10.279694,4.527,14.918056,11.911944,0.7984918,11.973116,14.856884,1.2408535,876793664,-7.9851193,5.9266624,15,America/New_York,EDT,False,False,USD,-2.61,us_market,"Fulcrum Therapeutics, Inc.",NGM,POST,2,0.63361937,1630531634,27.0,0.17000008,-9.663302,26.65 - 29.9,29.7,26.82,27.0,9,9,finmb_376267397,NasdaqGM,"Fulcrum Therapeutics, Inc.",USD,3295537,1036633,19.98,2.9167883,6.85 - 29.9,-3.0699997,-0.10267558,6.85,29.9,1620304200,1620304200,0,1620304200,-14.919,-3.36,-14400000,,,,29.9,6.85,14.92,11.97,3.3M,1.04M,32.68M,,17.56M,11.50%,80.96%,678.59k,9.65,3.82%,2.08%,743.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-543.14%,-34.74%,-69.93%,12.86M,0.47,538.50%,-46.84M,-67.42M,-69.37M,-14.92,,143.86M,4.41,4k,0.00,6.49,4.53,-54.68M,-26.04M,Value,02139,Healthcare,73,9,8,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 651 8851,MA,8,1609372800,1622505600,8,United States,http://www.fulcrumtx.com,86400,9,26 Landsdowne Street,Biotechnology
t-3,FULC,122131000,32679600,3380000.0,,-15685000,,-15685000,5149000,-10775000,-15924000,-15924000,,,,,,0,2000000,17924000,12775000,239000,,-15685000,-15685000,306961000,22731000,122131000,5023000,144862000,27000,208000,-184938000,8788000,81000,1168000,75718000,13943000,81000,8910000,134784000,56020000,960000,3571000,-16000.0,-1237000.0,-226000.0,-12000.0,64686000.0,515000.0,64891000.0,50339000.0,-14121000.0,553000.0,-430000.0,2163000.0,-210000.0,-70000.0,-193000.0,120841000,en-US,US,EQUITY,True,Nasdaq Real Time Price,26.83,1630526403,-2.8700008,29.64,29.9,26.65,956551,-10.279694,4.527,14.918056,11.911944,0.7984918,11.973116,14.856884,1.2408535,876793664,-7.9851193,5.9266624,15,America/New_York,EDT,False,False,USD,-2.61,us_market,"Fulcrum Therapeutics, Inc.",NGM,POST,2,0.63361937,1630531634,27.0,0.17000008,-9.663302,26.65 - 29.9,29.7,26.82,27.0,9,9,finmb_376267397,NasdaqGM,"Fulcrum Therapeutics, Inc.",USD,3295537,1036633,19.98,2.9167883,6.85 - 29.9,-3.0699997,-0.10267558,6.85,29.9,1620304200,1620304200,0,1620304200,-14.919,-3.36,-14400000,,,,29.9,6.85,14.92,11.97,3.3M,1.04M,32.68M,,17.56M,11.50%,80.96%,678.59k,9.65,3.82%,2.08%,743.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-543.14%,-34.74%,-69.93%,12.86M,0.47,538.50%,-46.84M,-67.42M,-69.37M,-14.92,,143.86M,4.41,4k,0.00,6.49,4.53,-54.68M,-26.04M,Value,02139,Healthcare,73,9,8,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 651 8851,MA,8,1609372800,1622505600,8,United States,http://www.fulcrumtx.com,86400,9,26 Landsdowne Street,Biotechnology
